Previous 10 | Next 10 |
home / stock / eprx:cc / eprx:cc news
Eupraxia Pharmaceuticals Reports First Quarter 2023 Financial Results Canada NewsWire VICTORIA, BC , May 11, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an inn...
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire VICTORIA, BC , April 20, 2023 /CNW/ - Eupraxia Pharmaceut...
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2022 Financial Results Canada NewsWire VICTORIA, BC , March 23, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an i...
Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis Canada NewsWire - Company remains on track for Phase 2 data readout in Q2 2023 - VICTORIA, BC , Dec. 7, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc....
Eupraxia Pharmaceuticals Reports Third Quarter 2022 Financial Results Canada NewsWire VICTORIA, B.C. , Nov. 7, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with a...
Eupraxia Pharmaceuticals Appoints Chief Business Officer Canada NewsWire --Industry Veteran Paul Brennan Appointed Effective Nov 1 st -- VICTORIA, BC , Nov. 1, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (...
Eupraxia Pharmaceuticals Initiates Phase 2 Study in Eosinophilic Esophagitis Canada NewsWire -Represents second Phase 2 program for EP-104IAR, with initial data readout anticipated in H1, 2023- VICTORIA, BC , Oct. 12, 2022 /CNW/ - Eupraxia Pharmaceuti...
Eupraxia Pharmaceuticals Provides Update for Phase 2 Study in Knee Osteoarthritis for Lead Drug Candidate EP-104IAR Canada NewsWire -- Clean Safety Review from Data Safety Monitoring Board Supports Addition of Diabetes Patients into the Trial -- VICTORIA, BC ...
Eupraxia Pharmaceuticals Announces Expansion of Intellectual Property For EP-104IAR Canada NewsWire VICTORIA, BC , Sept. 26, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology ...
Eupraxia Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference Canada NewsWire VICTORIA, BC , Sept. 7, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology compan...
News, Short Squeeze, Breakout and More Instantly...
Eupraxia Pharmaceuticals Inc. Company Name:
EPRX:CC Stock Symbol:
TSXC Market:
Eupraxia Pharmaceuticals Inc. Website:
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo Canada NewsWire VICTORIA, BC , July 8, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnolo...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 Canada NewsWire Osteoarthritis ("OA") is the leading cause of disability in older adults. The U.S. Centers for Disease Control an...
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders Canada NewsWire VICTORIA, BC , June 6, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. (" Eupraxia " or the " Company ") (TSX: EPRX) (NASDAQ: EPRX), a cli...